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Utrophin and dystrophin present two large proteins that link the intracellular actin cytoskeleton to the extracellular matrix via
the C-terminal-associated protein complex. Here we describe a novel short N-terminal isoform of utrophin and its protein
product in various rat tissues (N-utro, 62 kDa, amino acids 1–539, comprising the actin-binding domain plus the first two spectrin
repeats). Using different N-terminal recombinant utrophin fragments, we show that actin binding exhibits pronounced negative
cooperativity (affinity constants K1 = ∼ 5 × 106 and K2 = ∼ 1 × 105M−1) and is Ca2+-insensitive. Expression of the different
fragments in COS7 cells and in myotubes indicates that the actin-binding domain alone binds exlusively to actin filaments. The
recombinant N-utro analogue binds in vitro to actin and in the cells associates to the membranes. The results indicate that N-utro
may be responsible for the anchoring of the cortical actin cytoskeleton to the membranes in muscle and other tissues.
1. Introduction
Utrophin and dystrophin are large (395 and 427 kDa, resp.)
modular proteins that link the cytoskeletal F-actin filaments
to the plasmalemma. The C-terminal portion including the
cysteine-rich domain associates with over a dozen of different
scaffold and signaling proteins (utrophin-/dystrophin-as-
sociated protein complexes, UAPC and DAPC). These com-
plexes are coupled via the transmembranous beta-dystro-
glycan to alpha-dystroglycan and to the extracellular matrix
(ECM) proteins. At their N-terminus, both proteins contain
a homologous actin-binding domain composed of a pair of
calponin homology motifs (CH1 and CH2 in tandem) that
are connected to the long sequence of spectrin-like triple
helical repeats, 22 in utrophin and 24 in dystrophin. The
spectrin repeat sequences are interspersed by hinges (H1–
H5) giving these structural molecules flexibility (Figure 1).
Thus, these two cytoskeletal proteins directly link the intra-
cellular cytoskeleton to the ECM in muscle and nonmuscle
tissues.
In striated muscle, full-length dystrophin (Dp427) local-
ises to the inner side of the plasma membrane (sarcolemma)
with its N-terminus binding to nonmuscle beta- and gamma-
actin in the costameres which physically couple to the Z-disc
of force-generating myofibres [1]. Dp427 is thought to pro-
vide mechanical stability for the muscle fibre and the neces-
sary flexibility of its anchoring to the surrounding ECM dur-
ing contraction and extension; in fact, it may act as a
cellular “shock-absorber” [2, 3]. Loss of functional Dp427
causes severe muscle wasting in the fatal Duchenne’s
muscular dystrophy (DMD). The muscle symptoms can
be improved, at least in the dystrophic mdx mouse model,
by transgenic expression of Dp427 or by expression of
engineered shorter versions of dystrophin comprising the
essential constituents for binding to actin and the sarco-
lemma [4–6]. In addition, overexpression of full-length
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Figure 1: Domain structure of utrophin (rat) and dystrophin (human). Numbers denote amino acid (aa) residues according to rat utrophin.
The short N-terminal utrophin isoform (N-utro) extends from aa 1 to 539. The black sections UT11, UT12, UT21, UT31, and DYS12 were
used for heterologous expression in bacteria and eukaryotic cells. The recombinant proteins were used for production of antibodies, for in
vitro actin-binding studies, and for eukaryotic cell transfection. AB, actin-binding domain; H1–H5, hinge regions; R1–R24, spectrin-like
triple helical repeats; CR, cystein-rich domain; CT, C-terminal domain.
utrophin (Up395) in Fiona mice lacking Dp427 localises
along the sarcolemma resulting in complete recovery of
normal mechanical functions and prevents the occurrence
of muscular dystrophy [7, 8]. The Fiona mouse line overex-
presses Up395 under a human alpha-actin promoter in
skeletal muscle, but not in the heart, over 20 times compared
to control mice.
Based on the homologous domain structure (Figure 1)
and the high amino acid (aa) sequence similarity, utrophin
and dystrophin are expected to serve comparable functions.
In fact, in fetal animals utrophin prevails and localises to the
sarcolemma like dystrophin in the adult. During postnatal
maturation of striated muscle, Up395 disappears from the
sarcolemma and becomes restricted to the neuromuscular
(NMJ) and myotendinous junctions [9]. Thus, utrophin can
functionally replace dystrophin. Nevertheless, there are sig-
nificant differences between the two during spaciotemporal
development, in tissue and subcellular localisation, in iso-
form complement, and, on a molecular level, in actin-
binding properties [4, 10–12]. DMD (X-linked recessive dis-
order) is the most common lethal disease in childhood con-
cerning 1 in 3500 boys. In addition, about one-third of DMD
patients display mental retardation related to alterations in
integrated brain circuits [13]. This points to vital functions of
these skeletal proteins other than muscle membrane stability.
The DMD gene localises to human chromosome Xp21
and comprises 79 exons and at least 7 internal promoters
[14]. The protein Dp427 is mainly expressed in skeletal and
cardiac muscle and to a lesser extent in the nervous system.
It derives from three independent promoters (M: muscle;
B: brain, P: cerebellar Purkinje cells) consisting of spliced
unique first exons that regulate specific expression. In adult
skeletal muscle, Dp427 is located at the sarcolemma and in
the troughs of the postsynaptic membrane. Its N-terminal
actin-binding domain contains aa 1–246 (Figure 1). Four
shorter nonmuscle products harboring the cysteine-rich
and C-terminal domains, but lacking the N-terminal actin
binding domain, are expressed from downstream promoters
and have been named according to their molecular weights,
Dp260, Dp140, Dp116, and Dp71 [14, 15]. Dp71 has been
detected in cardiac muscle and most nonmuscle tissues
including brain, retina, kidney, liver, and lung [11, 12, 16,
17].
The gene of utrophin, paralogous to DMD, is located
on human chromosome 6q24 containing 75 exons and 6
internal promoters [18, 19]. Up395 is named utrophin be-
cause of its ubiquitous tissue distribution in comparison to
Dp427. Expression of Up395 is driven by two independent
promoters UtrnA and UtrnB [20]. The UtrnA protein is
the main isoform in adult skeletal muscle and appears in
the NMJ at the crests of the postsynaptic membrane folds
in association with the nicotinic acetylcholine receptors
(AchR). The UtrnB isoform is found enriched in vascular
endothelium. Both Up395 isoforms are, however, found in
brain structures and in many other tissues as well [11, 20].
As for the DMD gene, the internal utrophin promoters give
rise to several shorter C-terminal isoforms with preservation
of the cysteine-rich and the C-terminal domains, which
correspond to the similar short isoforms from dystrophin
and thus also lack the N-terminal actin-binding domain
[14, 19, 21]. Up140 corresponds to DP140, Up113 (also
called G-utrophin) to Dp116, and Up71 to Dp71.
While no short N-terminal dystrophin isoform is known,
we have described the cloning of a transcript from the
utrophin locus in rat C6 glioma cells which codes for a
short N-terminal utrophin isoform (N-utro). N-Utro aa 1–
539 comprises the actin-binding domain (Ch1 and CH2)
plus the first two spectrin-like repeats (Figure 1) [22].
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By immunoblotting with monoclonal antibodies (mABs)
against aa 1–261 (N-terminal actin-binding domain) of utro-
phin, a 62 kDa fragment was earlier detected in rat C6 glioma
cells [23]. This finding suggested the existence of a truncated
N-terminal form of utrophin that was confined to the
glioma cells. Indeed, its apparent molecular mass in sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) precisely matches that of N-utro. Here we confirm the
expression of mRNA for N-utro in all rat tissues examined
including skeletal and cardiac muscle, brain, kidney, and
liver. The expression of the N-utro protein could be verified
in cardiac muscle and kidney.
Recombinant utrophin fragments aa 2–594 (correspond-
ing to N-utro), aa 2–261 (actin-binding domain), aa 262–543
(first two spectrin repeats), aa 1754–2091 (spectrin repeats
R14–R16), and the dystrophin fragment aa 1–246 (actin-
binding domain) were heterologously expressed in E. coli
and in eukaryotic cells (Figure 1, black domains). These
fragments were used for production of polyclonal antibodies
(pABs) and for testing actin-binding function. Transfection
of COS7 cells and myoblasts allowed to follow intracellular
localisation by immunostaining. As this novel N-terminal
fragment (N-utro) is added to the panoply of the short utro-
phin isoform family, it is important to characterise its genet-
ics and functional potential.
2. Material and Methods
2.1. Recombinant Protein Expression. Three fragments from
rat utrophin (UT11, UT12, and UT31) and two from human
muscular dystrophin (DYS11 and DYS12) were cloned into
pQE vectors (Qiagen) for expression in Escherichia coli
M15[pREP4] (Figure 1). This provides a MRGSH6 tag at
the Nterminus of the proteins. In order to maintain the
correct reading frame, one to two additional amino acids
(aa) appeared between the tag and the in-frame proteins
(see below). For DYS12, the DNA coding for aa 1–246
was cloned into the blunted BamHI site of pQE-32 after
PCR amplification from a human dystrophin minigene with
the following sense and antisense primers 5′-ATGCTT-
TGGTGGGAAGAAGTA-3′ and 5′-TATTCAATGCTCACT-
TGTTGAGGC-3′, respectively. The dystrophin minigene in
pUC18 (44) was kindly provided by Dr. S. J. Winder. The
other four pQE expression plasmids contain DNA fragments
obtained by restriction digestion. For the DYS11 plasmid
which codes for aa 1–617, the minigene was digested with
NcoI, blunted, and digested with NarI, and the resulting
NarI-NcoI-fragment was ligated into the NarI HincII-site of
the DYS12 plasmid; the UT11 plasmid coding for aa 2–594
is a blunted EaeI-EaeI-fragment of clone α-213 ligated into
the blunted BamHI site of pQE-30; for production of the
UT12 plasmid coding for aa 2–261, clone α-213 was digested
with BsaHI, blunted, digested again with StuI, and the thus
resulting StuI-BsaHI fragment was then ligated into the StuI-
HincII site of the UT11 plasmid; for the UT31 plasmid
coding for aa 1754–2091, the clone α-215 was first digested
with BamHI to produce a 2.7 kb fragment that was subcloned
into a pBluescript II SK vector (Stratagene Ltd) from which a
BamHI-HincII fragment was ligated into the BamHI-HincII
site of pBluescript II SK again from which a BamHI-KpnI
fragment was ligated into the BamHI-KpnI site of pQE-31.
All ligation junctions were sequenced for checking the
correct reading frame. Due to restriction cloning, a variable
number of vector-derived aa were attached to the C-terminus
of the proteins. The following final expression constructs
were obtained (numbers in brackets refer to the rat utrophin
or human dystrophin primary structure):
UT11: MRGSH6GS-(2–594)-RSACELGTP
GRPAAKLN,
UT12: MRGSH6GS-(2–261)-GPAAKLN,
UT31: MRGSH6T-(1754–2091)-SRGGPVPRV
DLQPSLIS,
DYS11: MRGSH6GI-(1–617)-DLQPSLIS,
DYS12: MRGSH6GI-(1–246).
All five described plasmids could be expressed in
Escherichia coli by induction with isopropyl-β-D-1-thiogal-
actopyranoside (IPTG) and purified by affinity chromatog-
raphy on Ni-nitrilotriacetic acid agarose (Qiagen). UT11,
UT12, and DYS12 were purified under native conditions by
elution with 200mM imidazole (example given in Figure 2).
UT31 and DYS11 could only be extracted and purified
under denaturing condition in 8M urea with elution from
the affinity column at pH 4.5. All protein preparations
were tested by SDS-PAGE. Protein concentrations were
determined by the Bradford test [24] with BSA as standard
and by UV absorption at E280 with extinction coefficients
of 87′580M−1cm−1 for UT11, 39′620 for UT12, 52′040
for DYS12, and 106′700 for DYS11 as derived from GCG
software.
2.2. RNA Isolation. RNA was isolated from different rat
tissues, brain, heart, kidney, liver, skeletal muscle, and C6
glioma cells [25] and passed twice over an oligo(dT) cellulose
column (New England Biolabs) for preparation of poly(A)+
RNA [26].
2.3. RT-PCR. 1 μg poly(A)+ RNA was mixed with 1 μg
pd(N)6 or with 0.86 μg oligo(dT)12−18 primers, in water
and incubated for 5min at 70◦C. The reverse transcription
was done according to manufacturer manual; in brief, the
RNA-primer complex was mixed with 200UM-MLV reverse
transcriptase (Promega, USA), 500 μM dNTPs each, 50mM
Tris-Cl pH 8.3, 75mMKCl, 3mMMgCl2, 10mMDTT, 25 μL
reaction volume. First strand cDNA was synthesised at 37◦C
for 2 h, stopped with 45 μL 77mM EDTA/0.23MNaOH, and
heated to 95◦C for 5min. After mixing with 18 μL 1M Tris-
Cl pH 8.0, the first strand cDNA was extracted with equal
volumes of phenol, phenol/chloroform, and chloroform,
precipitated with ethanol/NH4Ac and resolved in 50 μL TE.
PCR was performed in a volume of 50 μL containing
1U Taq polymerase (HotStar, Qiagen), 200 μM dNTPs each,
0.3 μMprimer each, 1x PCR buffer (Qiagen), 1 μL first strand
cDNA. Cycles were 95◦C 10min, followed by 40 cycles 30 sec
94◦C, 30 sec 60◦C, 60 sec 72◦C. PCR products were analysed
on a 1% agarose gel (see Table 1).
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Figure 2: Detection of the mRNA for the N-utrophin isoform and for full-length Up395 in rat tissues by RT-PCR and electrophoresis
in 1% agarose with ethidium bromide. (a) Organisation of mRNA for full-length utrophin (upper line) and for N-utrophin (lower line)
with direction of primers (lettered arrows) and exon borders (dashed lines). Sequence homolgy breaks down at nucleotide (nt) 1803. Non-
discriminating primers (A, B, C, D) recognise both isoforms, while primers (E, F, G) are specific for N-utrophin, and primers (H, J) are
specific for full-length utrophin. The genomic DNA contains intron-13 of 1.2 kilobases (kb) between exon-13 and 14. Exon numbering is
in homology to that of dystrophin. (b) RT-PCR (40 cycles) products ranging in size from 100 to 500 base pairs (bp) from poly(A)+ RNA of
rat kidney primed with either oligo(dT) or pd(N)6. (c) RT-PCR (40 cycles) products (AF and AG) from genomic rat liver DNA display sizes
of 1.5 and 1.7 kb containing intron-13 which adds 1.2 kb to each fragment. Product (EG) of 0.28 kb is specific for N-utrophin as control.
The three black lanes between EG and the markers (M) are controls with the same primer pairs but without DNA. (d) RT-PCR (30 cycles)
products (EG specific for N-utrophin and HJ specific for full-length utrophin) in different tissues. Black lanes are negative controls without
reverse transcriptase. Note the larger amount of N-utrophin message in skeletal muscle of young rats (postnatal day 8) as compared to adult
(arrow). Pairs of letters denote primer pairs; M stands for DNA markers.
2.4. Western Blots. Rat tissues from liver, brain, kidney,
heart, skeletal muscle, aorta, and uterus were collected, im-
mediately frozen in liquid nitrogen, and crushed to powder
using a mortar. 100 μL tissue lysis buffer per 10mg tissue was
added (62.5mM Tris-Cl pH 6.8, 5% sucrose, 5mM EDTA,
2% SDS and protease inhibitor (Complete Mini, Roche)),
and the lysate was homogenised three times for 20 sec with a
polytron (Kinematica) and centrifuged at 20,000 g for 5min
at 4◦C. The supernatant was collected and used for analysis.
Lysates were boiled in 50mM Tris-Cl pH 6.8, 2% SDS,
5% glycerol, 10mM DTT and run on 4–15% gradient SDS-
PAGE [27]. Blotting of the gel was performed in 7mM Tris,
87.5mM glycine, pH 8.3 (without methanol) using a Mini
Trans-Blot Cell (BioRad). After staining with Ponceau-S,
the membranes were cut into appropriate lanes for incuba-
tions with different antibodies and antisera (see legends of
Figure 3). After incubation with the primary antibodies and a
horseradish-peroxidase- (HRP-) labelled secondary antibody
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Table 1: Primer used for PCR (for localisation of primers along the cDNA, see Figure 2(a)).
Forward primer Backward primer
A Rut13F B Rut23B
C Rut14F D Rut24B
E Rut18F F Rut25B
G Rut28B
H Rut19F J Rut41B
PCR product size
A-B: 110 bp
A–D: 215 bp
A–F: 326 bp
A–G: 499 bp
C-D: 96 bp
C–F: 207 bp
C–G: 380 bp
E-F: 103 bp
E–G: 276 bp
H-J: 104 bp
Primer sequnce
Forward primer
RUT 13F 5′ CAA AGT GAC CTC GAA GCT GAG C 3′ rat utrophin 1587−→1608
RUT 14F 5′ GGG TGA GCG CTG GAC AGC TG 3′ rat utrophin 1706−→1725
RUT 18F 5′ GTG CAA CGA CCA TCC ATC AAG G 3′ rat N-utrophin 1810−→1831
RUT 19F 5′ GTC TTT TGG AAG CTT GGC TCA CC 3′ rat utrophin 1804−→1826
Backward primer
RUT 23B 5′ AAC TGA TCT TCC AAA ACA GCT GTG 3′ rat utrophin 1673←−1696
RUT 24B
5′ TGT TCT TCC AAT AAT TCC TGC CAC 3′ rat N-utrophin
1778←−1801
RUT 25B 5′ TTC CAG AGC TCT CAC TAC AGA AG 3′ rat N-utrophin 1890←−1912
RUT 28B 5′ CCC CAG AAT TAC GAA GGT CAC AC 3′ rat N-utrophin 2063←−2085
RUT 41B 5′ CAG ACG CCG GAC ACT GAC ACC 3′ rat utrophin 1887←−1907
detection was performed by SuperSignal chemiluminescence
(Pierce). The different membrane lanes were precisely re-
joined together and exposed to Fuji’s medical X-ray film
(Fuji Photo Film). Controls were done by omission of the
first antibody, by using preimmune serum (not shown)
and by competition with the appropriate antigen, 10 μg/mL
(Figure 3). Molecular weight markers spanning the range
from 14.4 kDa lysozyme up to 200 kDa myosin were used
(BioRad, broad-range markers).
2.5. Antibodies and Antisera. Antibodies used were mon-
oclonal Abs (mAb) NCL-DYS1 (Novocastra Laboratories),
anti-actin monoclonal IgM (Amersham Life Science), goat
anti-rabbit IgG-HRP (Pierce) and goat anti-mouse IgM-
HRP (Pierce). New Zealand white rabbits and guinea pigs
were immunised with purified recombinant UT11 and UT31
together with Freund’s adjuvant [22]. Prior to immunisation
the 26 N-terminal aa of recombinant UT11 and UT31, were
sequenced for confirmation. The recombinant proteins were
run on 10% SDS-PAGE and eluted for sequencing after
electroblotting onto polyvinylidene difluoride membranes.
2.6. Actin-Binding Assay. Actin-binding assays were done
according to Zuellig et al. [22]. Binding results are given
as affinity constant K which corresponds to the reciprocal
value of the dissociation constant KD. In brief, varying
concentrations of the recombinant protein fragments UT11,
UT12, DYS12, or BSA in actin-binding buffer (50mM Tris-
maleate pH 7.4, 0.1M NaCl, 1mM ATP, 1mM DTT, and
either 0.5mM CaCl2, 2mM MgCl2 or 5mM EGTA, 6mM
MgCl2 were dialysed for 15 hours with one buffer change at
4◦C. Purified F-actin (6 μM) [28] from rabbit fast skeletal
muscle was added and the samples incubated for 30min at
25◦C in 100 μL volume. Cosedimentation was carried out
in a Beckman TLA-100 tabletop ultracentrifuge for 30min
at 100,000 g at 25◦C. Equal amounts of supernatant and
pellet were run on 10% SDS-PAGE, stained with Coomassie
Blue R250, and analysed with the Image Analysis System
MCID/M2 (Imaging Research) integrating the area of the
protein bands.
For the EGTA studies, the fragments (all 10 μM) were
dialysed at 4◦C for 40 h with three buffer changes into a
buffer containing 50mMHEPES/NaOH pH 7.4, 0.1MNaCl,
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Figure 3: Immunoblots of rat tissues for full-length utrophin and N-utrophin (4–10% SDS-PAGE). (a) Adult tissues with protein loads of
∼45 μg (1x), ∼90 μg (2x), and ∼90 μg for C. All lanes stem from one gel blotted onto nitrocellulose membrane. After staining with Ponceau-
S, the membrane was cut for separate immunostaining (1x and 2x together plus lane C separate). Lanes 1x and 2x were incubated with
anti-UT11. Anti-UT11 recognises full-length (∼395 kDa) and N-utrophin (∼65 kDa). C Lanes present competition by preincubation of the
serum with recombinant UT11 antigen (10 μL/mL serum) before loading onto the blot. In addition, actin (∼44 kDa) was visualised in brain
tissue by mixing anti-actin antibody with anit-UT11. Finally, the differently incubated membrane lanes were precisely joined together for
exposure on X-ray films. Full-length utrophin is seen in all tissues and N-utrophin in kidney and heart. Competition with UT11 antigen
removes full-length and N-utrophin. The second lower band underneath the full-length utrophin may represent a degradation product
which is, however, only partially removed by antigen competition. (b) The same approach was employed with the gel comprising H, M, and
C, except that anti-actin antibody was added to all lanes for loading control and as internal molecular size marker. Protein load was ∼90 μg
protein of heart (H) and muscle (M) from young (8 days postnatal) and adult tissues. N-Utrophin can only be seen as a faint band in young
heart tissue (arrow). The band of full-length utrophin is greatly reduced in adult muscle (double arrow) and abolished by competition in all
samples labeled with C. For comparison, C6 rat glioma cells stained with anti-UT11 displaying full-length and N-utrophin as well as adult
muscle stained with anti-DYS12 (a) and NCL-DYS1 (b) derived from different gels are included.
1mMATP, 1mMDTT, 6mMMgCl2, and the corresponding
combination of EGTA/CaCl2 (in mM) 0/0.5, 0.5/1.0, 1.0/1.5,
5.0/6.0. Purified F-actin (10 μM) was added and processed as
described above.
For the calmodulin (Sigma-Aldrich) studies, the pro-
cedure was as described above except the actin and UT11
or UT12 concentrations were kept constant at 10 μM, and
the buffer for dialysis and binding contained the following
combinations of EGTA/CaCl2/calmodulin (all in mM) 0/1/0,
1/0/0.2, 0/1/0.2, 1/2/0.2.
2.7. Circular Dichroism. FivemMdithiothreitol was added to
the purified recombinant proteins before dialysis into 10mM
Tris-Cl, pH 7.4, plus either 0.5mM CaCl2 or 1mM EGTA
plus 1.5mM CaCl2 for 40 hours with three buffer changes at
4◦C. Samples were analysed by circular dichroism at 25◦C in
a Jasco J 715 spectropolarimeter with a path length of 1mm.
Samples from two different preparations were analysed at a
concentration range of 1.5–3.1 μM with scanning from 260
to 190 nm. Data was processed according to [29] and the
alpha-helix content derived by infinite analysis.
2.8. Eukaryotic Expression Vectors. pBSGFP was constructed
by cutting pEGFP-N1 (Clontech Laboratories, Inc.) with
EcoRI and NotI, isolating the 0.7 kb EGFP-coding sequence,
and ligating it into he EcoRI-NotI site of pBluescript
II SK− (Stratagene Ltd). pBKΔlacI was generated by cutting
pBK-CMV (Stratagene Ltd) with the restriction enzymes
NheI-XbaI and religating the 4.27 kb fragment. pEUT11-
Flag contains the rat utrophin sequence from aa 1 to 543
followed by the Flag peptide (DYKDDDDK); the rat utro-
phin sequence from clone α213 [22] was amplified by PCR
with the primers Rut15F: 5′-TACCATGGACGGGCACCT-
TG-3′ (NcoI, nt189–>210) and Rut26B: 5′-ATGCGGC-
CGCTACTTATCGTCGTCATCCTTGTAATC-AGCTTCCA-
AAAGACACTGTTC-3′ (NotI, FlagTag, nt1817–>1797);
the resulting product was ligated into the NcoI-NotI site of
pBSGFP resulting in pBSxEUT11-Flag. This vector was cut
with Bsp120I and NotI, the resulting 1.7 kb fragment with
part of the 5′UTR, the utrophin sequence, and the FlagTag
was ligated into the Bsp120I and NotI site of pBKΔlacI vector
pEUT12 Flag contains the rat utrophin sequence 1–261
followed by the Flag peptide and was constructed the same
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way as pEUT11 Flag with the primer Rut15F and Rut27B:
5′-ATGCGGCCGCTACTTATCGTCGTCATCCTTGTAATC-
GTCTATAGTGACTTGCTGAGG-3′(NotI, FlagTag, nt 971–
>951) pEUT21 Flag contains the rat utrophin sequence 262–
543 followed by the Flag peptide and was constructed
the same way as pEUT11-Flag with the primer Rut16F:
5′-TACCATGGCCATTCGAGAGGTGGAGACG-3′ (NcoI,
nt 972–>992) and Rut26B.
2.9. Cell Culture. COS7 cells (ATCC-Nr: CRL 1651) were
cultivated at 37◦C/5%CO2 in Dulbecco’s modified Eagle’s
medium (DMEM, Sigma-Aldrich) supplemented with 10%
FCS (Sera-Tech), nonessential amino acids (Sigma-Aldrich),
and freshly added L-glutamine (complete DMEM).
Primary cultures of mammalian skeletal muscle cells
were initiated from neonatal myogenic cells obtained by
trypsinisation of muscle pieces from hind limbs of 1- to 3-
day-old neonatal rats. For three days following plating, cells
were maintained in growth medium (300 μMCa2+), consist-
ing of HAM F12 (Invitrogen SARL, Cergy Pontoise/France)
with 10% heat-inactivated horse serum (Invitrogen SARL),
10% fetal calf serum (Invitrogen SARL), and 1% antibiotics.
Myoblasts underwent myogenesis in differentiation medium
(1.8mM Ca2+), containing DMEM (Invitrogen SARL) sup-
plemented with 5% heat-inactivated horse serum. After 48 h
of culture, this control medium (DMEM + serum) was used
to promote the formation of myotubes, which occur within
15 to 18 h. The fusion-promoting conditions were provided
by the presence of a higher calcium concentration (1,8mM)
and horse serum. This medium exchange was used as time
zero for the differentiation.
2.10. Transfections. COS7 cells were seeded at 2 × 105 cells
per dish (4 cm diameter) and grown over night. The next
day, they were used for transfections. 3 μg plasmid DNA in
75 μL DMEM were mixed with 6 μL Superfect Transfection
Reagent (Qiagen) vortexed and incubated for 7min at 37◦C.
After washing the cells once with PBS, 0.5mL DMEM
mixed with the DNA-Superfect complex was added and
the cells incubated for 3 h at 37◦C/5%CO2. The cell were
washed twice with PBS, and 2mL complete DMEM per dish
was added and the cells cultivated for 24–48 h. After 48 h
of culture, myotube formation was induced which occurs
within 15–18 h. Two days later, the cells were used for
immunocytochemistry.
Proliferatingmyoblasts were transfected with the plasmid
cDNA by the Effectene Reagent kit (Qiagen, Courtaboeuf,
France). Cells were cultured for 36 hours on glass coverslips
(50 × 104 cells) in proliferating medium. Cells were rinsed
twice in fresh culture medium, and transfection of 1 μg of
plasmid cDNA per 35mm plastic dish was performed in the
presence of 8 μL enhancer for compacting cDNA and 10 μL of
the effectene cationic lipid. Following a 16 hour incubation,
the transfection mixture was replaced with fresh complete
proliferating medium.
2.11. Immunocytochemistry. COS7 cells were washed 3 times
for 2min with PBS and fixed in 4% paraformaldehyde,
0.15M sodium phosphate buffer pH 7.4 for 15min, washed
3 times 2min with PBS, and permeabilised with 0.1%
Triton-X-100 in 10% normal goat serum (Sera-Tech) in
PBS for 10min. Primary antibodies were applied in PBS,
10% normal goat serum for 1 h at RT. Cells were washed
3 times 2min with PBS, then the second antibodies were
added in PBS, 10% normal goat serum for 1 h at RT.
Cells were washed 3 times 2min with PBS, then they were
covered with glycerol gelatine (Merck) and viewed with a
Carl Zeiss Axioplan2 microscope. Antibodies used were anti-
FLAG-M2 mouse monoclonal antibody (Stratagene Ltd.),
rabbit anti-UT11, rabbit anti-UT31, goat anti-mouse IgM
conjugated to Oregon green (Molecular Probes Inc.) goat
anti-rabbit conjugated to Cy3 (Jackson Immunoresearch
Lab.) F-actin was visualised with rhodamine-phalloidin
(Molecular Probes Inc.).
Myoblasts and myotubes were fixed with 4% parafor-
maldehyde in TBS (20mM Tris-HCl, pH 7.5, 150mM NaCl,
2mM EGTA, 2mMMgCl2) for 20min at room temperature,
washed three times with TBS, and incubated with 0.5%
Triton X-100/TBS for 10min to improve permeability to the
reagents. After 10min of exposure to a blocking solution
(TBS containing 1% bovine serum albumin; Sigma), fixed
cells were incubated 1 h with an anti-Flag-M2 monoclonal
mouse antibody (1 : 1000). Samples were then exposed 1 h
in the dark to a 1 : 200 diluted FITC-conjugated goat anti-
mouse antibody (Jackson Immunoresearch, West Grove, Pa,
USA) altogether with TRITC-conjugated phalloidin (Sigma)
for directly staining F-actin microfilaments. Samples were
mounted using Vectashield mounting medium (Vector,
Burlingame, Calif, USA). The immunolabelled samples were
examined by confocal laser scanning microscopy (CLSM)
using a BioRad MRC 1024 ES (BioRad, Hemel Hempstead,
UK) equipped with an argon-krypton gas laser. The TRITC
fluorochrome was excited with the 568 nm yellow line, and
the emission of the dye was collected via a photomultiplier
through a 585 nm long pass filter. The FITC fluorochrome
was excited with the 488 nm blue line, and the emission
of the dye was collected via a photomultiplier through a
522 nm band pass filter. Data were acquired using an inverted
microscope (Olympus IX70, Tokyo, Japan) through a×60 oil
immersion lens and processed with the Laser Sharp software,
version 3.0 (BioRad). All the images were performed at equal
excitation intensities (10% of the laser power) with a variable
confocal aperture, a gain of 1500 and a black level of −3.
2.12. Statistics. Data evaluation was done using nonlinear
regression analyses with GraphPad Prism version 2 (Graph-
Pad Software). Values are mean ± standard error of the
mean. Statistical analysis was performed using ANOVA and
unpaired Student’s t-test. Significance was accepted at P <
0.05.
3. Results
3.1. mRNA of N-Terminal Utrophin Isoform (N-Utro, aa
1–539) in Different Tissues. We previously described the
message and protein of the short isoform N-utro in C6
rat glioma cells [22]. Here, we identify its presence in
different rat tissues. 1st strand cDNA prepared from tissue
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poly(A)+ RNA served as template for specific probing for
the occurrence of N-utro mRNA by PCR. The schematic
cDNA structures for full-length utrophin (Up395) and
N-utro in the region of interest around nucleotide 1803
are given in Figure 2(a). The two sequences are identical
down to nt 1802 where the deviation from Up395 begins in
N-utro with GTA, immediately followed by the stop codon
TGA. The protein sequence of N-utro is thus identical to
that of Up395 except for the last residue which in N-utro
is Val instead of Cys in Up395. N-Utro comprises the two
calponin homology domains, CH1 and CH2, followed by
the first two spectrin-like repeats and ends with amino acid
(aa) residue 539 (Figure 1). The GT motif at the start of
the sequence diversion could represent an unused splice
donor site, followed by intron material that is completely
different from the sequence in Up395 [22]. This allowed the
construction of forward and backward primers specific for
either the N-utro or the Up395 sequence in order to identify
the respective molecular species by PCR (Figure 2(a)). Puta-
tive exon-intron boundaries (dashed lines) are given in anal-
ogy to their positions in the dystrophin gene.
The 1st strand cDNA was obtained from rat kidney
poly(A)+ RNA, primed with either oligo(dT) or pd(N)6.
As oligo(dT) priming starts at the 3′ end and might some
times stop within the sequence, we also employed pd(N)6
random hexadeoxynucleotide for priming which starts at
corresponding sites along the sequence [30]. On agarose
gels, all primer pairs yielded the same distinct bands with
both methods in RT-PCR (Figure 2(b)). The AB product is
a 110 bp fragment encoded by exon-13, AD comprises exon-
13 plus exon-14, and CD only exon-14. All three fragments
are shared by Up395 and N-utro. In contrast, the products
AF, AG, CF, and CG comprising exon-13 and/or exon-14
plus different lengths of intron-14 are specific for N-utro. EF
and EG derive from the N-utro-specific intron-14. To rule
out possible transcription artefacts and to confirm correctly
spliced N-utro RNA, genomic rat liver DNAwas directly sub-
jected to PCR with the following primer pairs, AF, AG, and
EG, (Figure 2(c)). Both the AF and AG products comprise
now the 1.2 kb intron-13 (see Figure 2(a)) increasing their
size with a corresponding slower electrophoretic migration
in the agarose gel (from 0.3 kb to 1.5 kb for AF and from
0.5 kb to 1.7 for AG). The size of EG remains unchanged since
it derives entirely from intron-14. Thus, splicing N-utro from
genomic DNA does not alter fragment size.
For detection of the N-utro splice variant poly(A)+ RNA
was isolated from different tissues and pd(N)6-primed for
production of 1st strand cDNAs. These were subjected to RT-
PCR with primers yielding the products EG (276 bp) specific
for N-utro and HJ (104 bp) specific for full-length Up395
(Figure 2(d)). Both species are seen in all tissues examined,
brain, heart, kidney, liver, and skeletal muscle. The message
for N-utro (EG) appeared in all tissues lower than for those
Up395 (HJ). Different primer pairs do, however, not allow
comparative quantification since expression efficacy may
vary between different primer pairs. On the other hand, the
N-utro message (primer pair EG) was clearly fainter in adult
skeletal muscle than inmuscle from 8 days old rats or in adult
heart. The same holds for the full-length-utrophin Up395-
specific primer pair HJ. Quantitative comparison between
one primer pair from the same gel under identical conditions
is valid.
3.2. Utrophin and N-Utro Protein in Different Tissues. West-
ern blots on 4–15% gradient SDS-PAGE were performed
with all tissues where the mRNAs for Up395 and N-utro have
been analysed (Figure 3). The polyclonal antibodies (pABs)
raised against the recombinant utrophin fragments and
DYS12 proved specific and did not cross-react. Probing with
anti-UT11 clearly revealed Up395 in all tissues (Figures 3(a)
and 3(b)) including C6 rat glioma cells which was added
for comparison (Figure 3(b)). As expected, Up395 was
drastically reduced in adult (double arrowhead) skeletal
muscle when compared to muscle from 8 days old rats
(P8). The protein bands migrating at ∼62 kDa indicated
by arrows in heart and kidney may represent the N-utro
protein as they coincide in position with the N-utro band
in C6 cells. Furthermore, the disappearance of the bands of
Up395 and N-utro by competition with an excess of UT11
antigen (columns headed by C) supports the suggestion that
the band at ∼62 kDa indeed represents the N-utro pro-
tein. Together with the fact that the message for the N-
utro isoform is well expressed in these tissues (kidney and
heart in Figure 2(d)), the corresponding protein we observed
seems to represent N-utro. The higher molecular weight
bands between Up395 and N-utro in heart and kidney are
only partially outcompeted by UT11 antigen and may thus
represent utrophin degradation products comprising the N-
terminal portion or nonspecific cross-reactions by the pri-
mary antiserum or the secondary antibodies. For position-
ing of full-length dystrophin (Dp427) in relation to Up395
adult muscle, samples were immunestained by anti-DYS12
(a, in Figure 3(b)) and by the commercial monoclonal
NCL-DYS1 antibody stemming from aa 1181–1388 in the
spectrin repeats 8 and 9 of the rod (b, in Figure 3(b)). The
actin stained with a monoclonal IgM antibody in brain
(Figure 3(a)), muscle, and heart (Figure 3(b)), was used for
loading control and as intrinsic molecular weight marker.
In general, the levels of mRNAs need not necessarily cor-
respond to the amount of protein expression. Nevertheless,
it was reported that in human NCl-60 cancer cells 65% of
the genes showed statistically significant transcript-protein
correlation [31]. We, thus, estimated the relative content
of Up395 by semiquantitative immunoblot densitometry in
the various tissues from 2 to 8 days young and 6 to 8
weeks adult rats (Table 2). Staining intensities (±SEM) were
all expressed in relation to that of adult liver tissue which
was taken as 100. For calibration, liver and/or adult heart
tissue was included in all electrophoretic runs. The results
indicate that young and adult liver and brain tissue comprise
similar amounts of Up395 protein, while young and adult
kidney and heart as well as young skeletal muscle display
significantly higher values. In adult muscle, Up395 is down
to 10% of that found in young muscle as expected. The high
Up395 content in adult aortic and uterine tissue is given for
comparison. The content of N-utro was generally too low for
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Table 2: Content of full-length utrophin in tissues from young (2–
8 days of age) and adult (6–8 weeks old) rats. Averages of den-
sitometric evaluation of immunoblots (SEM is given for averages
from 5 experiments or more; number n of experiments in brackets).
Values of adult liver are set at 100. For comparison, averages of 3
experiments are given for aorta and uterus. Relative band intensities
are always determined in runs together with adult liver and/or heart
for calibration. For experimental details, see the Methods section.
Tissue Young Adult
Liver (5) 117 ± 24∗ (17) 100
Brain (5) 139 ± 22∗ (5) 105 ± 13∗
Kidney (5) 229 ± 29 (6) 278 ± 27
Heart (8) 362 ± 38 (11) 299 ± 14
Skeletal muscle (12) 211 ± 18 (20) 21.0 ± 1.5∗∗
Aorta — (3) 569
Uterus — (3) 539
(∗) Significantly lower (P < 0.002) than young and adult heart and adult
kidney. (∗∗) Significantly lower (P < 0.0001) than any other tissue with n
of 5 or higher.
quantitative assessment (Figure 3). The relatively high Up395
content in adult heart and kidney and in young muscle
coincides with the brightest transcript bands for Up395 in
the agarose gels (HJ product in Figure 2(d)) pointing to
a correlation between message and protein expression. An
absolute protein content for Up395 of 0.0006% of total
protein was determined in adult mouse skeletal muscle [2,
32]. This is around 30 times less than dystrophin in adult
muscle (∼0.02%) and would allow to translate the relative
values from Table 2 into approximate protein content in the
different tissues.
3.3. Actin Binding of N-Terminal Fragments of Utrophin
and Dystrophin. Two types of recombinant N-terminal
fragments were prepared from utrophin and dystrophin for
in vitro actin-binding studies (Figure 1). UT12 (coding for
aa 2–261 = 31.6 kDa) and DYS12 (aa 1–246 = 29.9 kDa)
comprise the actin-binding domain (CH1 and CH2) alone.
Second, UT11 (aa 2–594 = 71.1 kDa) contains in addition
the first hinge region followed by two spectrin-like repeats
plus 68 aa running into spectrin repeat-3. This fragment is
taken as analogue to the N-terminal utrophin isoform (N-
utro) earlier isolated from C6 rat glioma cells which com-
prises the two spectrin-like repeats plus 13 aa of repeat-
3. As mentioned above, its primary sequence is identical
to that of rat utrophin except for the last residue of Cys
instead of Val. All three recombinant fragments bearing
a His-tag (MRGSH6GS-) at their N-terminus for affinity
purification on Ni-nitrilotriacetic acid (Ni-NTA) agarose
column could be eluted with 200mM imidazole under native
conditions. The affinity purification from expression in E.
coli is shown in SDS-PAGE (Figure 4). The electrophoretic
mobility of the purified protein fragments is also revealed
by immunoreaction with a mAB against the His-tag. Despite
its calculated molecular mass of 71.1 kDa, UT11 persis-
tently migrated at a somewhat lower position (with an
apparent molecular mass of ∼62 kDa) in SDS-PAGE. The
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Figure 4: Expression and purification of the recombinant utrophin
(UT11 and UT12) and dystrophin (DYS12) fragments used for in
vitro actin-binding studies. Fragments were expressed in E. coli
by induction with isopropyl-β-D-1-thiogalactopyranoside (IPTG),
subsequently purified by Ni-NTA (Ni-nitrilotriacetic acid) affinity
chromatography, and finally checked on 10% SDS-PAGE. Protein
staining with Coomassie brilliant blue R250 of bacterial expression
(lanes 1) and purified fragments (lanes 2). The fragments were also
immunostained with an anti-His-tag mAB.
DYS11 plasmid coding for aa 1–617 (74.0 kDa) presents
the homologue to UT11 in utrophin. Unfortunately, the
protein could only be extracted and eluted from Ni-NTA
agarose under denaturing conditions in 8M urea and pH
4.5. DYS11 could, therefore, not be used for actin-binding
studies. Renaturation by dialysis gradually approaching
“native” conditions without urea and pH 7 was unsuccessful.
Actin binding was assessed for UT11 (aa 2–594), UT12
(aa 2–261), and DYS12 (1–246) by high-speed (30min at
1000,000 g and 25◦C) cosedimentation with fast rabbit skel-
etal muscle actin filaments (see Material and Methods sec-
tion). SDS-PAGE was performed by loading equal volumes
of supernatant and resuspended pellet. Densitometric eval-
uation was executed after rigorously controlled staining and
destaining conditions yielding a linear relationship from 0.2
to 10 μg of protein under the assumption that all proteins
stained with equal intensity. Actin concentration was always
kept constant and thus served as internal loading standard,
while the potential ligand was varied. BSA (∼67 kDa) and
tropomyosin (subunit chain ∼33 kDa) were run with all
series in parallel for negative and positive controls of the
binding as well as control sedimentation of the ligands
in the absence of actin. The electrophoretic runs of an
example of UT12 binding to actin together with BSA as a
control are given in Figure 5. While BSA at all concentra-
tions occurs unbound in the supernatant (Figure 5(b)), the
bound as well as the unbound portion of UT12 increase
with ascending ligand concentration (Figure 5(a)). Traces of
probably\linebreak non-polymerised actin were occasionally
seen in the supernatants, never, however, exceeding 2% of
total actin.
Binding data and Scatchard plots of all experiments with
UT11, UT12, and DYS12 are given in Figure 6. All three
protein fragments exhibit saturation binding independent
of Ca2+ with UT11 and UT12, while Dys12 binding was
Ca2+-sensitive (inhibition with EGTA). UT11 andUT12 both
display a concave curve in the Scatchard plot indicating a
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Table 3: Actin binding of recombinant protein fragments of utrophin and dystrophin. Parameters are derived from the binding data given
in Figure 6.
Recombinant
protein
Amino
acids
Affinity constants (M−1) Binding sites per actin monomer
Correlation
coefficient
(r)
Total actin
monomers
per ligand at
high affinity
Total actin
monomer
per ligand
at
saturation
K1 K2 n1 n2
UT11 2–594 6.3 × 106 9.3 × 104 0.04 0.28 0.93 25 3.1
UT12 2–261 4.6 × 106 2.5 × 105 0.14 0.62 0.98 7 1.3
DYS12 1–246 1.3 × 105 3.7 × 105 1.90 (n1 plus n2) 0.98 — 1.9
Origin
of gel
Actin
UT12
0.1 0.2 0.4 1.0 3.3
SP SP SP SP SP
(a)
Molar ratio of UT12 to actin (actin 6 µM)
0.1 0.2 0.4 2.0
Origin
of gel
Actin
BSA
SP SP SP SP
(b)
Figure 5: Binding assay by cosedimentation of F-actin with UT12
and BSA for control. 10% SDS-PAGE with protein staining by
Coomassie brilliant blue R250. Pellet (P) and supernatant (S)
fractions with different molar ratios of UT12 (a) or BSA (b) to actin
in the presence of 2mM MgCl2 and 0.5mM CaCl2. UT12 and BSA
varied from 0.6 up to 19 μM. Actin was held constant at 6 μM. The
positions of UT12, BSA, and actin are indicated at the left. Arrows
point to unbound UT12 in the supernatant. At all concentrations,
no BSA was bound to actin.
high affinity and a second lower affinity (Figures 6(b) and
6(d)). The binding parameters derived from Figure 6 are
summarised in Table 2. The affinity constant K corresponds
to the reciprocal value of the dissociation constant KD. The
higher affinity constant K1 is for both UT fragments around
5-6 × 106 M−1. The second lower K2 is for UT11 about
70 times lower and for UT12 about 20 times lower. Con-
cave Scatchard curves imply either the existence of two
types of binding sites on filamentous actin (F-actin), or
ligand-induced negative cooperativity. The two parts of the
Scatchard curves for UT11 and UT12 are sufficiently distinct
to allow separate evaluation. One molecule of UT11 binds
with high affinity per 25 actin monomers, while UT12
binds per 7 actin monomers with high affinity (Table 3).
This high stoichiometric relation is greatly reduced at full
saturation binding involving the two affinities together. Then
one molecule of UT11 binds per 3.1 actin monomers,
and UT12 binds per ∼1.3 actin monomers. The lower
binding stoichiometry for UT12 conforms to that reported
for the recombinant utrophin fragment (aa 1–261) which
corresponds to UT12 [33]. Winder and coworkers [34] have
reported an affinity of ∼5 × 104 M−1 for the binding of the
N-terminal utrophin fragment (aa 1–261) to muscle F-actin
with a stoichiometry of almost 1 : 2. Its affinity is, however,
∼100 times lower than that reported here for K1 and still 5
times lower than that of K2.
In contrast to the utrophin fragments, DYS12 (aa 1–
246 = actin binding domain) binding to F-actin in the ab-
sence of EGTA displays a sigmoidal saturation curve with
a lower slope at the beginning that increases with rising
ligand concentration before saturation sets (Figure 6(e)).
Such a sigmoidal binding curve is characteristic for positive
cooperativity and yields a typical convex Scatchard’s plot
(Figure 6(f)) with a Hill coefficient of 1.52. The combined
binding constant for DYS12 is 2-3× 105 M−1, and oneDYS12
molecule binds per 2 actin monomers. Reported stoichiome-
tries for recombinant N-terminal protein fragments from
utrophin (aa 1–261) and dystrophin (aa 1–246) are 1 : 1 and
2 : 1, respectively, [10, 33] which agrees with our results given
here. Affinities around 8 × 104 M−1 have been published for
several in vitro actin-binding studies with fragments from
utrophin and dystrophin [33]. Our K1 values for UT11
and UT12 are definitely higher by more than an order of
magnitude (Table 3). On the other hand, the binding affinity
of our DYS12 with a His-tag at its N-terminus is close to
7.3 × 104 M−1 reported [35] for a corresponding N-terminal
dystrophin peptide (aa 1–246) with the His-tag at its C-
terminus and also close to 5.3 × 104 M−1 published for an
untagged N-terminal peptide (aa 1–246) [36]. It may, there-
fore, be concluded that an attached His-tag does not gross-
ly affect actin binding.
The apparent Ca2+ sensitivity of DYS12 binding to actin
(inhibited by EGTA) concealed a peculiarity we first were not
aware of. In order to evaluate the free Ca2+ ion concentration
critical for the actin binding of DYS12, cosedimentation
assays were performed in a Ca2+-EGTA buffer system with
5mM EGTA and varying amounts of Ca2+. Surprisingly, at
all free Ca2+ ion concentrations up to 1mM, the binding of
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Figure 6: Binding of utrophin and dystrophin fragments to actin by cosedimentation. Assays were carried out in 2mM MgCl2 and 0.5mM
CaCl2 (O) or 6mM MgCl2 and 5mM EGTA (•). Saturation curves for binding of UT11 (a), UT12 (c), and DYS12 (e) at the left side with
the corresponding Scatchard plots at the right (b, d, f). The binding curves resulted from 7 separate experiments each. All data points (•) are
incorporated in the Scatchard plots except for DYS12 in the presence of EGTA. The concave Scatchard curves (b, d) indicate the presence of
a higher and a lower affinity due to either two classes of binding sites or, alternatively, negative cooperativity. The convex curve (f) suggests
positive cooperativity of DYS12 binding. Binding of DYS12 to actin was also measured with increasing concentrations of EGTA (g) in the
presence of 1mM CaCl2 in excess over the EGTA. Numbers at data points refer to the number of experiments. Error bars indicate SEM with
P < 0.001 for 0 and 0.5 versus 1.0 and 5.0mM EGTA. The small differences between 0 versus 0.5 and 1.0 versus 5.0mM EGTA were not
significant. For further explanation, see the text.
DYS12 never exceeded 30% of the maximal level obtained
in the absence of EGTA (data not shown). Therefore, in
further series of experiments, the EGTA concentration was
varied with always 0.5mM CaCl2 in excess over EGTA. The
results in Figure 6(g) indicate that the actin binding decreases
significantly at EGTA concentrations higher than 0.5mM.
No recovery of the actin binding was observed after removal
of EGTA by dialysis in the presence of 0.5mM CaCl2. Actin
sedimentation was not affected by the presence of EGTA
at any concentration used. EGTA up to 5mM never had
an affect on actin binding either of UT11 nor UT12. For
a rough estimation of possible protein structural changes,
circular dichroism (CD) measurements were performed on
UT12 and DYS12 in the absence of EGTA but with 0.5mM
Ca2+ and in the presence of 1.0mM EGTA plus 1.5mM
Ca2+ (spectra not shown). Both fragments exhibited a double
minimum under both conditions typical for proteins with a
high alpha-helical content. The results revealed a decrease of
alpha helix content by 16% for UT12 and by 18% for DYS12
in the presence of EGTA with CaCl2 in excess (Table 4).
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Table 4: Circular dichroism parameters of UT12 and DYS12 in the presence and the absence of EGTA each with an excess of 0.5mM CaCl2
(spectrum analysis from 190 to 260 nm, for details see the Method section).
UT12 UT12/EGTA DYS12 DYS12/EGTA
Alpha helix 60.0 50.9 62.4 51.1
Beta Sheet 0.3 0 0 0
Turn 12.7 19.2 14.0 23.2
Random 26.4 29.9 23.6 25.7
Total 100 100 100 100
RMS∗ 7.406 19.824 10.238 16.711
∗RMS: root mean square for performance quality.
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Figure 7: Effects of calmodulin and calcium on binding of UT11 and UT12 to actin. Calmodulin plus EGTA does not inhibit actin binding
(open symbols). Calmodulin plus Ca2+ (black symbols) does not inhibit actin binding of UT11 (a), but binding of UT12 is inhibited (b).
Incubation conditions: (O) Ca2+ 1mM; () calmodulin 0.2mM plus EGTA 1mM; (•) calmodulin 0.2mM plus Ca2+ 1mM; () calmodulin
0.2mM, Ca2+ 2mM plus EGTA 1mM (for further explanation see the text).
The reduction of alpha-helix was compensated for by an
increase in turns. The decrease in alpha-helix is of similar
magnitude in the two proteins and does not explain the
selective impairment of EGTA on the actin-binding function
of DYS12.
Winder and Kendrick-Jones [37] reported that actin
binding of recombinant UTR261 (aa 1–261) was inhibited
by calmodulin in the presence of Ca2+, but not in its absence.
We reproduced this result with the corresponding UT12 (aa
2–261) without and with additional EGTA (Figure 7(b)).
Surprisingly, calmodulin plus Ca2+ and also calmodulin,
2mM Ca2+ plus 1mM EGTA, which both inhibited binding
of UT12 did not affect actin binding of UT11 bearing two
spectrin repeats (Figure 7(a)).
3.4. Immunolocalisation of UT11, UT12, and UT21 in COS7
Cells and Myotubes. For evaluation of intracellular localisa-
tion of the actin binding domain alone (EUT12, aa 1–261),
the actin-binding domain plus the first two spectrin repeats
(EUT11, aa 1–543) and the two first spectrin repeats R1 and
R2 alone (EUT21, aa 262–543) were inserted into eukaryotic
plasmids for transfection to COS7 cells (Figure 8) as well
as to myoblasts (Figure 9). For unambiguous recognition,
all three recombinant fragments were fused to the “FLAG”
peptide (-DYKDDDDK) at their C-terminus which can be
detected by anti-Flag M2 mAB. Actin was visualised in
double staining with rhodamine-phalloidin. Transfection
efficiency was directly assessed by fluorescence microscopy
in a number of experiments in which a GFP containing
second plasmid was included. The transfected cells displayed
unaltered shape and growth compared to nontransfected
cells in phase contrast analysis.
COS7 cells are derived from monkey’s kidney and im-
mortalised by an origin-defectivemutant of SV40 [38]. These
cells are often used for transfection with recombinant plas-
mids, and during growth they readily adhere to glass and
plastic surfaces. Spread on the substratum the cells display a
fibroblast-like appearance (Figures 8(a), 8(c), and 8(e) at the
right). The cytoskeletal actin (probably beta- and gamma-
actin) appears in stress fibre structures and in densely organ-
ised cortical cytoskeleton along the cell surface membrane.
In the left vertical row (a–f), anti-FLAG staining reveals
the recombinant utrophin proteins. EUT12 (actin-binding
domain) follows the same pattern by staining all actin struc-
tures outside the cell nucleus (Figures 8(c) and 8(d)). EUT21
(first two spectrin repeats) localises in the cell nucleus and
does not associate with actin (Figures 8(e) and 8(f)). Anti-
UT31 (against the rod) faintly stains endogenous full-length
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Figure 8: Intracellular sorting of utrophin fragments by expression of eukaryotic vectors in COS7 cells (EUT11, EUT12, and EUT21, all
carrying the FLAG-tag at the C-terminus). Cells in the vertical row at the left are all stained with the anti-Flag M2 mAB ((a), (b), (c), (d),
(e), (f)). Rhodamine-phalloidin staining for actin displays stress fibres and a dense cortical actin cytoskeleton along the cell membranes in
the COS7 cells spreading on the substratum ((a), (c), (e) at the right). Anti-UT11 recognises full-length utrophin and N-utrophin giving
intensive staining in and around the nucleus that results from the heterologously expressed EUT11 plus the endogenous utrophin ((b) at
the right). Anti-UT31 (spectrin 14–16 in the rod) stains COS7 cells diffusely throughout the cytoplasm without marking any defined actin
structures ((d), (f) at the right). EUT21 (first two spectrin domains) exclusively concentrates in the nuclei ((e), (f)). EUT12 (actin-binding
domain alone) precisely traces the actin microfilaments and the cortical cytoskeletal structures ((c), (d)). For further explanation see the
text.
utrophin (Up395) in the entire cell (d the at right). EUT11
(actin-binding plus two spectrin domains) is found in and
around the cell nucleus but also throughout the cell body
and faintly along the membrane (Figures 8(a) and 8(b)).
This distribution of the FLAG-labeled EUT11 is underlined
by anti-UT11 (b the at right) that intensely stains EUT11
plus the endogenous utrophin. Taken together, only the
isolated actin-binding domain of utrophin (EUT12) clearly
associates with stress fibres and submembranous cortical
actin structures. The relatively diffuse staining of Up395 with
anti-UT11 and anti-UT31 throughout the cells lets assume
that additional portions of the intact molecule other than the
actin and the first two spectrin domains must be involved in
specific target sorting.
Transfection with the cDNA plasmids encoding the
utrophin fragments EUT11, EUT12, and EUT21 fused to the
FLAG Tag was performed on myoblasts from neonatal rat
hindleg muscle in primary cell cultures. After 48 h of culture,
myotube formation was induced, and two days later the fixed
cells were immunostained for the utrophin fragments with
FITC-conjugated AB and with TRITC-conjugated phalloidin
for F-actin microfilaments. Staining patterns were assessed
by confocal laser scanning microscopy (Figure 9). The anti-
Flag stained utrophin fragments are displayed in the left
14 Journal of Biomedicine and Biotechnology
20 µm
EUT21
myoblast
20 µm
EUT21
myotube
EUT11
20 µm
20 µm
20 µm
20 µm
EUT12
EUT12
EUT11
myoblast
myotube
myotube
myotube
(a)
(b)
(c)
(d)
(e)
(f)
Figure 9: Intracellular sorting of utrophin fragments by expression of eukaryotic vectors inmyoblast andmyotube primary cultures (EUT11,
EUT12, and EUT21, all carrying the FLAG-tag at the C-terminus). In each picture in the left vertical row ((a)–(f)), one transfected cell (green)
is present stained with anti-FLAG for the corresponding utrophin fragment. Staining with rhodamine-phalloidin for actin reveals a variable
number of red cells in each picture ((b)–(e) in the right vertical row) indicating that the transfected cells often fuse with nontransfected
cells when forming myotubes. EUT11 and EUT21 solidly stain nucleus and cytoplasm in single spindle-shaped myoblasts. EUT12 (actin-
binding domain) sharply stains actin microfilaments ((c) and (d)) superimposable to the red pattern of actin stain ((c) and (d) at the right).
EUT12 also concentrates in regions where actin may attach to the substratum (d). EUT11 distributes over the cytoplasm in a diffuse and
punctate manner (b) leaving the myotube nuclei unstained. In contrast, EUT21 is almost exclusively confined to the cell nuclei. For further
explanations, see the Methods section and the text.
vertical row in green, while F-actin is stained in red in the
right vertical row. In all cases there appears only one trans-
fcted green cell (Figures 9(b)–9(e)). Evidently the transfected
myoblasts often fuse to myotubes together with nontrans-
fected cells. In the spindle-shaped myoblasts (Figures 9(a)
and 9(f)), staining for EUT11 and EUT21 fills the entire
cell including the nucleus. The myotubes (Figures 9(b)–9(e))
display a rich filamentous actin structural network, probably
mostly nonmuscle beta- and gamma-isoforms of the cortical
cytoskeleton. Sarcomere structures are not yet visible except
for just a beginning in the nontransfected myotube in red at
the top of Figure 9(b). EUT12 (actin-binding domain alone)
staining precisely follows the actin structures throughout
the myotubes and becomes especially dense at the ends
where the cells adhere to the substratum (Figures 9(c) and
9(d)). EUT11 staining does not follow the actin filaments
but remains diffuse and punctate, sparing out the nuclei.
Its staining pattern suggests that EUT11 may attach to the
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myotube surface membrane. EUT21 seems almost entirely
confined to a row of nuclei in Figure 9(e).
The general staining patterns of the three recombinant
fragments from the N-terminal utrophin region in myotubes
and in COS7 cells are similar in kind. The isolated actin-
binding domain (EUT12) clearly associates with F-actin
structures in both cell types, while the other two protein frag-
ments more variably appear in the cytoplasm, along the
membranes or in the cell nuclei.
4. Discussion
4.1. mRNA and N-Utro Protein in Rat Tissues. The occur-
rence of message and protein of a novel N-terminal short
utrophin isoform (N-utro) in different rat tissues is reported
here for the first time. In addition, its intracellular sorting as
well as in vitro actin-binding properties was examined. The
message for full-length utrophin (Up395) is the highest in
cardiac muscle, in skeletal muscle of early postnatal animals,
and in kidney. It is apparently lower in adult skeletal muscle,
brain, and liver (product HJ in Figure 2(d)). Although a
quantitative correlation between protein and message can
often not be demonstrated, in this case the Up395 content
(expressed relative to that in adult liver) was significantly
higher in those tissues where the message was also higher
(Table 1). This correlation between message and protein is
remarkable in view of the notorious difficulties encountered
with quantitative immunoblotting involving transfer of large
proteins such as Up395 to nitrocellulose membranes for
electrophoresis. Correspondingly, the protein N-utro could
be only visualised by immunoblots in those tissues with
the highest message levels for kidney and cardiac muscle
(Figure 3). In the other, tissues its content was too low for
detection.
4.2. Actin Binding. Since N-utro is the only N-terminal short
isoform possessing the actin-binding domain known so far,
extensive binding studies were done with the recombinant
analogue UT11 (aa 2–594, actin-binding domain plus two
spectrin repeats) in comparison to UT12 (aa 2–261) and
DYS12 (1–246), the latter two comprising the actin-binding
domain alone (Figures 6 and 7 plus Table 3). Several of the
findings presented here shed light on fundamental differ-
ences in actin-binding function between these N-terminal
fragments of utrophin and dystrophin.
First, the high- and low-binding affinities for UT11 and
UT12 greatly affect the stoichiometric relation of ligand to
actin. With the high affinity, UT11 binds to every 25th actin
and UT12 to every 7th actin. The two additional spectrin
repeats in UT11 differentiate the two utrophin fragments
from one another. These twomotifs of UT11must be respon-
sible for the more extended spacing of this ligand as com-
pared to UT12. With saturation binding the second lower
affinity reduces the spacing of the ligands along the F-actin
filament to ∼3 actin per UT11 and close to one actin per
UT12. In our experiments, there were no additional proteins
present such a tropomyosin or troponin components that
could impart a defined spacing periodicity. Thus, the high
affinity binding results suggest that UT11 with two spectrin
repeats affects the actin filament binding properties over a
distance of 25 actin monomers. But on increasing ligand
saturation, additional UT11 molecules seem able to asso-
ciate with actin at lower affinity in between those already
bound with high affinity. The overall stoichiometry is, thus,
reduced to three actin monomers per UT11. A similar delib-
eration applies to the shorter UT12 without spectrin repeats.
With high affinity, the actin-binding domain alone affects
the accessibility of 7 actins in the filament, while on satura-
tion including low-affinity binding, the stoichiometry drops
to ∼1 : 1. Taken together, our results suggest, under the as-
sumption of indistinguishable binding sites of the individual
actin monomers in the filament, that the distinct lower af-
finity is induced by the binding of the ligands UT11 and
UT12 with high affinity. Furthermore, in view of the different
spacing induced by UT11 or UT12 binding with high
affinity, it seems most unlikely that a second class of defined
binding sites with lower intrinsic affinity exists along the
actin filament. Several reports on N-terminal utrophin and
dystrophin fragments mention similar actin-binding affini-
ties in the range of ∼105 M−1 and similar stoichiometries
for binding saturation as given here [33–35, 39]. However,
these published binding affinities may routinely represent the
lower values at full saturation, while the higher values at low
ligand concentrations of utrophin fragments may have been
overlooked. Actin-binding studies have mostly been per-
formed with skeletal muscle alpha-actin. Yet the cytoskeletal
Up395 and Dp427 primarily interact in vivo with cytosolic
beta- and gamma-actin which are ubiquitously expressed.
Even in striated muscle, the cortical gamma cytoskeletal
actin in the costameres between the sarcolemma and the Z-
disks presents the interaction partner for Up395 and Dp427
[40]. Nevertheless, the different actin isoforms share over
93% sequence identity and can replace each other to a large
extent [40]. Reassuringly, it was reported that the bind-
ing characteristics of utrophin and dystrophin and their frag-
ments to nonmuscle actin are almost identical to those with
skeletal muscle actin [8, 33–35]. The binding affinities are in
some cases slightly higher for cytoplasmic than for skeletal
muscle actin.
Second, in stark contrast to the negative cooperativity in
the binding of the utrophin N-terminal fragments, DYS12
binds to actin filaments with moderately positive cooperativ-
ity (Hill coefficient of 1.5) and a stoichiometry at saturation
of one ligand per two actin monomers. Positive cooperativity
with a Hill coefficient of 3.5 was also reported for actin bind-
ing of the dystrophin fragment (aa 1–246) that corresponds
to UT12 [6, 36]. Tropomyosin was reported to affect neither
affinity nor stoichiometry in the binding of dystrophin in
vitro [39, 41]. Curious enough, Up395 and Dp427 both bind
to actin by lateral association along the actin filament but do
not compete in their binding with one another [2]. Dp427
comprises 5 basic spectrin repeats within the stretch of R11
to R17 in the middle of the rod. This spectrin repeat stretch
firmly associates with F-actin and reinforces the binding of
the N-terminal domain to actin. The actin interaction of
the spectrin repeat region is salt dependent pointing to its
electrostatic nature. The two actin-binding regions in dystro-
phin are separated by ∼1200 aa. Ervasti has presented a
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model for dystrophin as molecular shock absorber during
muscle contraction. On stretch the electrostatic interaction
of the positively charged spectrin repeats would slide along
the negative surface of the actin filament and, thus, dampen
elastic recoil [2]. This is not the case with Up395. Up395
lacks the basic nature of the corresponding spectrin repeats
in the middle of the rod, and, consequently, this stretch does
not interact with actin [42]. Instead, the 10 spectrin repeats
immediately following the N-terminal actin-binding domain
firmly interact with actin and stabilise the binding. This
interaction is not salt dependent and, thus, may be of hydro-
phobic nature. The N-terminal domain and the following
spectrin repeats function as a single contiguous unit [43].
This is compatible with the notion that UT11 with the
two first spectrin repeats occupies more actin monomers
than UT12. Consequently, it may be speculated that intact
Up395, because of its contiguous binding region from the N-
terminus through to spectrin repeat R10, does not function
as molecular shock absorber but rather as stabiliser of cor-
tical actin filaments in costameres and in the postsynaptic
membranes of NMJs [2, 4].
Finally, we assessed potential regulation by Ca2+ and
calmodulin of fragment binding to actin. The actin binding
of UT11 and UT12 proved to be independent of Ca2+ and
not affected by EGTA. However, the interaction of DYS12
with actin is virtually abolished in the presence of more than
0.5mM EGTA even in the simultaneous presence of 0.5mM
CaCl2 in excess. It was not possible to restore the binding
function to DYS12 by gradually removing EGTA in dialy-
sis. Molecular parameters derived from circular dichroism
measurements indicated a reduction of alpha-helix content
by around 17% for both fragments in the presence of 5mM
EGTA plus 6mM CaCl2. This does not explain the selective
abolition of DYS12 actin binding by EGTA. The inhibition
of actin binding of UTR261 (or UT12) by calmodulin in the
presence of Ca2+ was suggested to be due to its competitive
binding to the CH1 domain [37]. Immediately upstream of
the actin-binding sequence-2 (ABS2) near the C-terminus of
CH1 localises a highly hydrophobic stretch of 15 aa that may
accommodate calmodulin complexed to Ca2+. It is specu-
lated that this represents a mode of regulation in vivo for
the interaction of the N-terminal utrophin with actin. Our
results indicate, however, that the two spectrin-like repeats in
UT12 are sufficient to prevent such a calmodulin/Ca2+ mode
of regulation. In vivo with Up395 running along the actin
filament firmly bound from its N-terminal actin-binding
domain through to spectrin repeat R10, it is unlikely that
this part of the molecule responds to subtle Ca-calmodulin
regulation. Furthermore, these findings are of particular
interest in relation to the novel N-utro isoform.
4.3. Intracellular Sorting of N-Terminal Utrophin Fragments.
To define their intracellular localization, COS7 cells and
skeletal muscle myoblasts were transfected with the eukary-
otic vectors of N-terminal utrophin fragments bearing the
FLAG-Tag at their C-terminus for immunodetection:
EUT11 (aa 1–543, CH1-CH2 actin-binding domain
plus first two spectrin repeats);
EUT12 (aa 1–261, CH1-CH2 actin-binding domain
alone);
EUT21 (aa 262–543, the first two spectrin repeats
alone).
After spreading on the substratum, the COS7 cells dis-
play a fibroblast-like appearance as revealed by staining of
the actin cytoskeleton with rhodamine-phalloidin (Figure 8).
Differentiation and myotube formation were induced in
the myoblasts by adding 1.8mM CaCl2 and horse serum
(Figure 9). As soon as the spindle-shaped diffusely staining
myoblasts fuse to myotubes, an intensely stained cytoskele-
ton develops with cytoplasmic actin filaments filling the
entire tubes. Only in one nontransfected myotube an early
expression of sarcomeric striation can be seen (Figure 9(b)).
In both types of cells, the transfected EUT12 neatly tracks
the actin cytoskeleton and accumulates at the edges where
the myotubes attach to the substratum. In the myotubes, the
actin fibres could serve as scaffold for the nascent myofi-
brils as we have described earlier for the remodeling of
rat cardiomyocytes in long-term culture [44]. Recombinant
UTR261-GST (glutathione S-transferase) fusion-protein mi-
croinjected into chick embryo fibroblasts was shown to label
stress fibres and focal contacts [34]. The diffuse staining for
EUT11 comes as a surprise. Its repartition extends through-
out the cells. In the myotube, it leaves the nuclei unstained
and probably lines the membranes. Intact Up395 recognised
by anti-UT31 against the rod domain (spectrin repeats R14–
R16) presents a discrete, diffuse staining throughout the
COS7 cells (Figures 8(d) and 8(f)). This indicates that Up395
probably also lines the cell membrane attached to the cortical
actin cytoskeleton, but it does not mark any stress fibre-
like structures. Yet another feature holds for EUT21 which
distinctly marks the nuclei, probably invading them.
Taken together, the staining pattern of EUT12 for actin
filaments and of EUT11 for membranes may be interpreted
as follows. The actin-binding domain alone (UT12 and
EUT12) binds to actin filaments with high affinity in a
Ca2+-independent manner. The actin binding plus first two
spectrin domains (UT11 and EUT11) associate with mem-
branes preventing the N-terminus to bind to actin stress
fibre-like structures, though the N-terminus may still bind
strongly to the cortical actin network lining the membranes.
In other words, the two spectrin repeats associated with
membranes, prevent the N-terminus from going astray by
following the actin filaments throughout the cell body.
UT11 and EUT11 correspond to the N-utro isoform, whose
genomic derivation and protein we have described here.
Thus, N-utro (1–539) may function as an ultrashort linker
between cortical actin and the membranes. These properties
may gain functional significance when N-utro was present
in sufficiently high concentration. In molecular terms, N-
utro is ∼6 times smaller than full-length Up395 and could
represent a significant molecular fraction. Moreover, its
repartition in different tissues could be concentrated at
specific subcellular structures such as neural synapses or in
epithelial and endothelial cell systems involved in barrier,
secretory, and resorptive function as in kidney nephrons,
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vasculature, or blood-brain barrier. In all these cases, scaffold
and signaling platforms require highly specialised subcellular
localisation for interaction with myriads of proteins and
other components [11, 12, 16, 17, 45].
5. Conclusions
We describe here a novel type of utrophin isoform that
derives from its N-terminus (N-utro). The various C-
terminal isoforms of utrophin and dystrophin correspond
to each other except for Dp260 which has no analogue in
utrophin. N-Utro also presents an exception as no analogous
N-terminal isoform from dystrophin is known so far. N-
utro has no relation to the utrophin/dystrophin-associated
protein complex. Consequently, the function of N-utro
seems to differ from that of the full-length or C-terminal iso-
forms. Our immunocytochemical results indicate that N-
utro could be responsible for the anchoring of the cortical
actin cytoskeleton to the membranes. Possible association of
N-utro with additional proteins other than actin needs fur-
ther exploration.
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